Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin for Reducing the Risk of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

NCT06342141 is registered in ClinicalTrials.gov with Instituto Nacional de Cardiologia Ignacio Chavez as lead sponsor.

NCT NCT06342141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06342141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin for Reducing the Risk of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 22, 2024
Completion date
June 15, 2026
Enrollment
162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

no-reflow phenomenon, stemi